Parkinson's disease is caused by the degeneration of dopaminergic brain cells, and most current treatments aim to replace dopamine or mimic its effects. Prexton Therapeutics' approach, however, is to stimulate a separate, compensatory neuronal system unaffected by Parkinson's. Its drug candidate Foliglurax (formerly known as PXT002331) activates a specific target of the glutamatergic system (mGluR4). The aim is to treat the motor symptoms of Parkinson's.
Merck & Co and Bristol-Myers Squibb both had mGluR4 programs that stalled
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?